Healthtech funding in H1 2016
European Healthtech startup funding raised during H1 2016.
In H1 2016, 163 European Healthtech companies closed 169 funding rounds and raised €1.1B in equity funding (excluding debt and grants), up 117.9% versus H1 2015. Debt rounds added €19M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.1B
+117.9% vs H1 2015 · excl. debt & grants · +€19M debt
Funding rounds
169
+94.3% vs H1 2015
Companies
163
Top country
UK
Rank among sectors
#4
8.4% of sector funding
Debt financing
€19M
1.8% of total
Top-10 round share
44.1%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2016 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €91M | 23 |
| Feb | €144M | 24 |
| Mar | €87M | 23 |
| Apr | €279M | 27 |
| May | €249M | 39 |
| Jun | €222M | 33 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2016 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2016 | |
|---|---|
| UK | €260M |
| Switzerland | €249M |
| Israel | €153M |
| France | €109M |
| Sweden | €62M |
| Netherlands | €49M |
| Spain | €35M |
| Germany | €30M |
Stage mix
by € raisedHealthtech — stage mix, H1 2016 — interactive chart.
Data table
| Healthtech — stage mix, H1 2016 | |
|---|---|
| Growth/Late | €411M |
| Series A | €170M |
| Series B | €147M |
| Series D+ | €89M |
| Series C | €82M |
| Early VC | €79M |
| Seed | €71M |
| Debt | €19M |
| Grant | €3.1M |
| Other | €650k |
Exits & M&A
11 Acquisition · 2 Merger · 1 IPO14 exits · €1.8B disclosed.
| Arcam | Acquisition | Feb 2016 | €636M |
| Valtech Cardio | Acquisition | Apr 2016 | €628M |
| EngMab | Acquisition | May 2016 | €545M |
Top deals
largest disclosed rounds in H1 2016| Company | Stage | Date | Amount |
|---|---|---|---|
| Oxford Nanopore Technologies | Growth/Late | Apr 2016 | €111M |
| MindMaze | Growth/Late | Feb 2016 | €92M |
| F2G | Growth/Late | Jun 2016 | €55M |
| AC Immune | Series D+ | May 2016 | €40M |
| CRISPR Therapeutics | Series B | Jun 2016 | €35M |
| MedDay | Series B | Apr 2016 | €34M |
| Impulse Dynamics | Growth/Late | May 2016 | €30M |
| NovImmune | Series D+ | Jan 2016 | €27M |
| G-Therapeutics | Series A | Apr 2016 | €26M |
| STAT-Diagnostica | Series C | Apr 2016 | €25M |
| Babylon Health | Growth/Late | Jan 2016 | €23M |
| EarlySense | Series D+ | Jun 2016 | €23M |
| Allecra Therapeutics | Series B | Jun 2016 | €22M |
| apotea.se | Growth/Late | May 2016 | €22M |
| Cambridge Epigenetix | Series B | Mar 2016 | €19M |
Top investors
most active in H1 2016, by deal count- High-Tech Gründerfonds (HTGF)7 deals
- Bpifrance5 deals
- Capricorn Partners4 deals
- Bayern Kapital3 deals
- Boehringer Ingelheim Venture Fund3 deals
- Invitalia Ventures3 deals
- IRDInov3 deals
- Pontifax Funds3 deals
- Principia SGR3 deals
- Scottish Investment Bank - Scottish Enterprise3 deals